AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts
AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts
Read moreThu, 20th Jun 2019 09:54
AIM WINNERS & LOSERS: Warpaint sees profit topping market forecasts
Read moreIN BRIEF: ValiRx inks evaluation agreement for breast cancer treatment
Read moreEARNINGS UPDATES: ValiRx reports narrowed loss; McBride revenue slips
Read more(Sharecast News) - Clinical-stage drug development company ValiRx updated the market on its patent portfolio on Tuesday, reporting that it had continued to build its intellectual property position in the first half of the year.
Read moreTRADING UPDATES: Brave Bison, Strix Group see strong performances
Read more(Sharecast News) - Clinical-stage drug development company ValiRx announced on Thursday that it has ended its agreement over the evaluation of the 'KTH222' peptide as a drug candidate for treating patients with ovarian cancer.
Read moreUK shareholder meetings calendar - next 7 days
Read moreEXECUTIVE CHANGES: Ex-Coca-Cola exec, Cafe Rouge founder for Deliveroo
Read moreTRADING UPDATES: Focusrite sales soar; Gaming Realms in Slingo boost
Read more(Sharecast News) - Oncology consulting company Physiomics has entered into a new agreement with clinical-stage drug development company ValiRx, it announced on Monday, superseding the agreement between the two companies, which was announced in September 2011.
Read moreIN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics
Read moreIN BRIEF: ValiRx's VAL201 Patented For Treatment Of Metastatic Cancer
Read moreUK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter
Read moreUK TRADING UPDATE SUMMARY: Joules In Lockdown Hit But Online Surges
Read moreValiRx Loss Narrows In First Half Amid Reduction In Expenses
Read more